Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 6 | 5 |
| List of Tables | 8 | 1 |
| List of Figures | 9 | 2 |
| Rheumatology Therapeutics Market to 2018 - Introduction | 11 | 1 |
| Introduction | 11 | 1 |
| Rheumatology Therapeutics Market to 2018 - Market Overview | 12 | 8 |
| Introduction | 12 | 2 |
| Revenue | 14 | 2 |
| Annual Cost of Treatment | 16 | 2 |
| Treatment Usage Pattern | 18 | 1 |
| Diseased Population | 19 | 1 |
| Diagnosed Population | 19 | 1 |
| Prescription Population | 19 | 1 |
| Rheumatology Therapeutics Market to 2018 - Geographical Landscape Revenue Analysis by Geography | 20 | 24 |
| The US | 20 | 1 |
| Revenue | 21 | 1 |
| Annual Cost of Treatment | 22 | 2 |
| Treatment Usage Patterns | 24 | 1 |
| Diseased Population | 25 | 1 |
| Diagnosed Population | 25 | 1 |
| Prescription Population | 25 | 1 |
| Top Five Countries of Europe | 26 | 1 |
| Introduction | 26 | 1 |
| Revenue | 26 | 3 |
| Annual Cost of Treatment | 29 | 1 |
| Treatment Usage Patterns | 30 | 1 |
| Diseased Population | 31 | 1 |
| Diagnosed Population | 31 | 1 |
| Prescription Population | 31 | 1 |
| Japan | 32 | 1 |
| Revenue | 32 | 2 |
| Annual Cost of Treatment | 34 | 2 |
| Treatment Usage Patterns | 36 | 1 |
| Diseased Population | 37 | 1 |
| Diagnosed Population | 37 | 1 |
| Prescription Population | 37 | 1 |
| Australia | 38 | 1 |
| Overview of Rheumatology Market | 38 | 1 |
| Rheumatoid Arthritis | 38 | 1 |
| Osteoarthritis | 38 | 1 |
| Gout | 38 | 1 |
| Systemic Lupus Arthritis | 39 | 1 |
| China | 40 | 1 |
| Revenue | 40 | 1 |
| Rheumatoid Arthritis | 40 | 1 |
| Osteoarthritis | 40 | 1 |
| Gout | 41 | 1 |
| Systemic Lupus Erythematosus | 41 | 1 |
| India | 42 | 1 |
| Overview of Rheumatology Market | 42 | 1 |
| Rheumatoid Arthritis | 42 | 1 |
| Osteoarthritis | 42 | 1 |
| Gout | 43 | 1 |
| Systemic Lupus Erythematosus | 43 | 1 |
| Rheumatology Therapeutics Market to 2018 - Therapeutic Landscape | 44 | 45 |
| Rheumatoid Arthritis Therapeutics Market | 44 | 1 |
| Introduction | 44 | 1 |
| Revenue | 45 | 3 |
| Revenue by Country | 48 | 2 |
| Annual Cost of Treatment | 50 | 1 |
| Treatment Usage Pattern | 51 | 1 |
| Diseased Population | 52 | 1 |
| Diagnosed Population | 52 | 1 |
| Prescription Population | 52 | 1 |
| Treatment Flow Algorithm | 53 | 1 |
| Drivers and Barriers for the Rheumatoid Arthritis Therapeutics Market | 53 | 1 |
| Drivers for the Rheumatoid Arthritis Therapeutics Market | 54 | 1 |
| Barriers for the Rheumatoid Arthritis Therapeutics Market | 54 | 1 |
| Osteoarthritis Therapeutics Market | 55 | 1 |
| Introduction | 55 | 1 |
| Revenue | 55 | 4 |
| Revenue by Country | 59 | 2 |
| Annual Cost of Treatment | 61 | 1 |
| Treatment Flow Algorithm | 62 | 1 |
| Treatment Usage Pattern | 63 | 1 |
| Diseased Population | 64 | 1 |
| Diagnosed Population | 64 | 1 |
| Prescription Population | 64 | 1 |
| Drivers and Barriers for the Osteoporosis Therapeutics Market | 65 | 1 |
| Drivers for the Osteoporosis Therapeutics Market | 65 | 1 |
| Barriers for the Osteoporosis Therapeutics Market | 65 | 1 |
| Gout Therapeutics Market | 66 | 1 |
| Introduction | 66 | 1 |
| Revenue | 66 | 4 |
| Revenue by Country | 70 | 2 |
| Annual Cost of Treatment | 72 | 1 |
| Treatment Usage Pattern | 73 | 1 |
| Diseased Population | 74 | 1 |
| Diagnosed Population | 74 | 1 |
| Prescription Population | 74 | 1 |
| Treatment Flow Algorithm | 75 | 1 |
| Drivers and Barriers for the Gout Therapeutics Market | 75 | 1 |
| Drivers for the Gout Therapeutics Market | 76 | 1 |
| Barriers for the Gout Therapeutics Market | 76 | 1 |
| Systemic Lupus Erythematosus Therapeutics Market | 77 | 1 |
| Introduction | 77 | 1 |
| Revenue | 78 | 3 |
| Revenue by Country | 81 | 2 |
| Annual Cost of Treatment | 83 | 2 |
| Treatment Usage Pattern | 85 | 1 |
| Diseased Population | 86 | 1 |
| Diagnosed Population | 86 | 1 |
| Prescription Population | 86 | 1 |
| Treatment Flow Algorithm | 87 | 1 |
| Drivers and Barriers for Systemic Lupus Erythematosus Therapeutics Market | 87 | 1 |
| Drivers for Systemic Lupus Erythematosus Therapeutics Market | 88 | 1 |
| Barriers for Systemic Lupus Erythematosus Therapeutics Market | 88 | 1 |
| Rheumatology Therapeutics Market to 2018 - Pipeline Analysis | 89 | 6 |
| Pipeline Assessment by Clinical Phase of Development | 89 | 1 |
| Key R&D Trends and Future Outlook | 90 | 1 |
| Profiles of Promising Molecules | 91 | 1 |
| Tofacitinib | 91 | 1 |
| Fostamatinib | 91 | 1 |
| LY2127399 (tabalumab) | 92 | 1 |
| Naproxcinod | 92 | 1 |
| RDEA594 (lesinurad) | 92 | 1 |
| BCX4208 | 93 | 1 |
| Epratuzumab | 94 | 1 |
| Lupuzor | 94 | 1 |
| Atacicept | 94 | 1 |
| Rheumatology Therapeutics Market to 2018 - Competitive Landscape | 95 | 10 |
| Abbott | 95 | 1 |
| Overview | 95 | 1 |
| Major Marketed Products | 95 | 1 |
| Humira | 95 | 1 |
| SWOT Analysis | 96 | 1 |
| Amgen | 97 | 1 |
| Overview | 97 | 1 |
| Major Marketed Products | 97 | 1 |
| Enbrel | 97 | 1 |
| SWOT Analysis | 98 | 1 |
| Pfizer | 99 | 1 |
| Overview | 99 | 1 |
| Major Marketed Products | 99 | 1 |
| Celebrex | 99 | 1 |
| Arthrotec | 99 | 1 |
| Enbrel | 100 | 1 |
| SWOT Analysis | 100 | 1 |
| Janssen Biotech | 101 | 1 |
| Overview | 101 | 1 |
| Major Marketed Products | 101 | 1 |
| Remicade | 101 | 1 |
| Simponi | 101 | 1 |
| SWOT Analysis | 102 | 1 |
| Merck | 103 | 1 |
| Overview | 103 | 1 |
| Major Marketed Products | 103 | 1 |
| Remicade | 103 | 1 |
| Simponi | 103 | 1 |
| SWOT Analysis | 104 | 1 |
| Rheumatology Therapeutics Market to 2018 - Strategic Consolidations | 105 | 8 |
| Overview | 105 | 1 |
| Deals by Type of Agreement | 106 | 1 |
| Deals by Year | 107 | 1 |
| Deals by Geography | 108 | 1 |
| Profiling of Major Deals | 109 | 1 |
| AstraZeneca to Acquire Ardea Biosciences, Gout Drug Maker, for $1.26 Billion | 109 | 1 |
| Takeda Pharma Completes Acquisition of Nycomed International for $13,681m | 109 | 1 |
| Savient Pharma Announces the Sale of the Company | 110 | 1 |
| NicOx Enters into Option Agreement with Ferrer Internacional | 110 | 1 |
| Sanofi Enters into Licensing Agreement with Winston Labs | 110 | 1 |
| Ablynx Enters into Third Co-discovery and Co-development Agreement with Merck Serono | 110 | 1 |
| Emergent BioSolutions Amends Licensing Agreement with Pfizer | 111 | 1 |
| AstraZeneca Enters into Licensing Agreement with Rigel Pharma | 111 | 1 |
| Astellas Pharma Enters into Co-Development Agreement with UCB for Cimzia | 111 | 1 |
| Bristol-Myers Squibb Enters into Co-development Agreement with Ono Pharma for Orencia | 112 | 1 |
| Abbott Labs Enters into Co-development Agreement with Biotest for BT-061 | 112 | 1 |
| Pfizer Japan Enters into Co-Promotion Agreement with Takeda Pharma | 112 | 1 |
| Rheumatology Therapeutics Market - Appendix | 113 | 8 |
| Market Definitions | 113 | 1 |
| Abbreviations | 113 | 1 |
| Bibliography | 113 | 3 |
| Research Methodology | 116 | 2 |
| Coverage | 116 | 1 |
| Secondary Research | 116 | 1 |
| Primary Research | 117 | 1 |
| Therapeutic Landscape | 117 | 3 |
| Epidemiology-based Forecasting | 118 | 1 |
| Market Size by Geography | 119 | 1 |
| Geographical Landscape | 120 | 1 |
| Pipeline Analysis | 120 | 1 |
| Competitive Landscape | 120 | 1 |
| Expert Panel Validation | 120 | 1 |
| Contact Us | 120 | 1 |
| Disclaimer | 120 | 1 |